Forward Pharma A/S (NASDAQ:FWP – Get Rating) and Avalo Therapeutics (NASDAQ:AVTX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
Earnings and Valuation
This table compares Forward Pharma A/S and Avalo Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Forward Pharma A/S||N/A||N/A||-$1.89 million||N/A||N/A|
|Avalo Therapeutics||$5.40 million||7.72||-$84.38 million||N/A||N/A|
Forward Pharma A/S has higher earnings, but lower revenue than Avalo Therapeutics.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Forward Pharma A/S||0||0||0||0||N/A|
Avalo Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 577.20%. Given Avalo Therapeutics’ higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Forward Pharma A/S.
Volatility & Risk
Forward Pharma A/S has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
This table compares Forward Pharma A/S and Avalo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Forward Pharma A/S||N/A||N/A||N/A|
Institutional & Insider Ownership
13.0% of Forward Pharma A/S shares are held by institutional investors. 71.5% of Forward Pharma A/S shares are held by insiders. Comparatively, 45.4% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Forward Pharma A/S beats Avalo Therapeutics on 7 of the 10 factors compared between the two stocks.
About Forward Pharma A/S
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
About Avalo Therapeutics
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.